Dupilumab Efficacy and Safety in Moderate-To-Severe Uncontrolled AsthmaEfficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma

Pediatrics - United States
doi 10.1542/peds.2018-2420ssss
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Academy of Pediatrics (AAP)

Related search

605 Efficacy and Safety of Dupilumab in Adolescent Patients With Moderate-To-Severe Atopic Dermatitis

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Efficacy and Safety of Dupilumab for the Treatment of Moderate-To-Severe Atopic Dermatitis in Adults

Oncotarget
Oncology
2017English

Efficacy and Safety of Treatment With Biologicals (Benralizumab, Dupilumab, Mepolizumab, Omalizumab and Reslizumab) for Severe Eosinophilic Asthma

Allergy: European Journal of Allergy and Clinical Immunology
AllergyImmunology
2020English

Ixekizumab Efficacy and Safety in Moderate-To-Severe Genital Psoriasis

British Journal of Dermatology
DermatologyMedicine
2018English

Dupilumab Improves Lung Function and Reduces Severe Exacerbation Rate in Patients With Uncontrolled, Moderate-To-Severe Asthma With or Without Comorbid Allergic Rhinitis: Results From the Phase 3 LIBERTY ASTHMA QUEST Study

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Bayesian Network Meta-Analysis to Assess the Comparative Efficacy and Safety of Treatments for Severe or Uncontrolled Asthma

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Dupilumab Consistently Improves Rhinoconjunctivitis-Specific Health-Related Quality of Life in Patients With Uncontrolled, Moderate-To-Severe Asthma and Comorbid Allergic Rhinitis: Results From the Phase 3 LIBERTY ASTHMA QUEST Study

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

615 Dupilumab Elicits Rapid and Sustained Improvements in Itch in Adults With Moderate-To-Severe Atopic Dermatitis

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Laboratory Safety of Dupilumab in Moderate‐to‐severe Atopic Dermatitis: Results From Three Phase III Trials ( LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS )

British Journal of Dermatology
DermatologyMedicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy